Pharmerica (PMC) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
UBS Raises Price Target on Pharmerica (PMC) to $27; Remains Neutral
May 9, 2016 8:53 AM EDTUBS reiterated a Neutral rating on PharMerica (NYSE: PMC), and raised the price target to $27.00 (from $22.00), following the company's 1Q earnings report. On its conference call management provided 2Q16 guidance of $500-510 mln in revenues, $30.9-$31.9 mln of adjusted EBITDA, and EPS of $0.46-$0.48.... More
